Sistema PD-L1 antibody

Sistema's PD-L1 antibody is a preclinical-stage monoclonal antibody being developed for the treatment of various cancers. It functions as an immune checkpoint inhibitor by binding to Programmed death-ligand 1 (PD-L1), thereby preventing its interaction with the PD-1 receptor on T-cells. This blockade restores and enhances the anti-tumor immune response. Developed by Moscow-based Sistema-BioTech, the project focuses on creating high-productivity clone-producers, suggesting a development path potentially aimed at biosimilar production or therapeutic protein manufacturing.

Other names

PD-L1 antibody clonePD-L-1 antibody clonePD-L 1 antibody clonePDL-1 antibody clonePDL1 antibody clonePDL 1 antibody clone